THRIVE-CAR-T Digital App
NCT06665295 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2026-04-01
Summary
The goal of this clinical trial is to learn if a digital mobile application called THRIVE-CAR-T is helpful for the care of patients undergoing CAR-T cell therapy. The main question\[s\] it aims to answer are whether the THRIVE-CAR-T app is feasible and acceptable to patients.
Conditions
- CAR T-Cell Therapy
Interventions
- BEHAVIORAL
-
THRIVE-CAR-T
The intervention will begin several weeks prior to CAR-T cell therapy and will continue up until 30 days post CAR-T cell therapy. THRIVE-CAR-T is an educational and interactive digital application on an iPad for patients as they navigate receiving CAR-T. THRIVE-CAR-T is self-administered and provides education about the CAR-T cell therapy process, with several features to promote coping skills training informed by various well-established supportive psychotherapy strategies (e.g., cognitive behavior therapy, mindfulness, positive psychology), engagement, and health behavior change including gamification strategies, videos of patients who received CAR-T, and optional content.
Sponsors & Collaborators
-
Patrick C. Johnson, MD
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-17
- Primary Completion
- 2026-11-01
- Completion
- 2026-12-31
Countries
- United States
Study Locations
More Related Trials
-
Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy
NCT05362331 ·Status: WITHDRAWN ·Phase: NA
-
A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy
NCT07335094 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
NCT07186192 ·Status: RECRUITING ·Phase: PHASE3
-
CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia
NCT04785833 ·Status: UNKNOWN ·Phase: NA
-
Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
NCT01935843 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of CAR-T Therapy in Older Patients
NCT04300998 ·Status: RECRUITING
-
Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
NCT01735604 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Long-term Follow-up Study of Patients Receiving CAR-T Cells
NCT03375619 ·Status: RECRUITING
-
Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma
NCT04840875 ·Status: COMPLETED ·Phase: PHASE1
-
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
NCT02311621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
NCT07055477 ·Status: RECRUITING ·Phase: PHASE1
-
Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
NCT01864902 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
NCT01621724 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors
NCT05621486 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors
NCT04691713 ·Status: UNKNOWN ·Phase: NA
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
NCT05366179 ·Status: RECRUITING ·Phase: PHASE1
-
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
NCT06617286 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
IVIG for Infection Prevention After CAR-T-Cell Therapy
NCT05952804 ·Status: RECRUITING ·Phase: PHASE2
-
Humanized CAR-T Therapy for Treatment of B Cell Malignancy
NCT02782351 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
NCT03638206 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
NCT02813837 ·Status: UNKNOWN ·Phase: NA
-
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors
NCT07152236 ·Status: RECRUITING ·Phase: NA
-
VitalTraq for the Detection of CRS
NCT06415656 ·Status: COMPLETED ·Phase: NA
-
Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies
NCT07345780 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
NCT04025216 ·Status: TERMINATED ·Phase: PHASE1